Bicycle Therapeutics (BCYC) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Bicycle Therapeutics (NASDAQ: BCYC) in the last few weeks:

• 11/8/2024 – Bicycle Therapeutics is now covered by analysts at Stephens. They set an “equal weight” rating and a $25.00 price target on the stock.
• 11/1/2024 – Bicycle Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.
• 11/1/2024 – Bicycle Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
• 10/31/2024 – Bicycle Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
• 10/24/2024 – Bicycle Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
• 10/24/2024 – Bicycle Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.

Bicycle Therapeutics Price Performance

Shares of BCYC opened at $20.48 on Wednesday. The firm has a 50 day simple moving average of $24.37 and a 200-day simple moving average of $23.10. Bicycle Therapeutics plc has a 1-year low of $13.07 and a 1-year high of $28.67. The stock has a market cap of $973.82 million, a price-to-earnings ratio of -6.22 and a beta of 0.89.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. The business had revenue of $2.68 million during the quarter, compared to analysts’ expectations of $6.82 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company’s revenue was down 50.0% on a year-over-year basis. During the same period last year, the company posted ($1.26) EPS. On average, equities analysts expect that Bicycle Therapeutics plc will post -3.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the completion of the sale, the chief accounting officer now directly owns 19,241 shares of the company’s stock, valued at approximately $483,141.51. The trade was a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin Lee sold 3,212 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the completion of the sale, the chief executive officer now directly owns 380,864 shares of the company’s stock, valued at $8,478,032.64. The trade was a 0.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 10,840 shares of company stock valued at $259,128. Company insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of Bicycle Therapeutics by 45.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock valued at $10,001,000 after purchasing an additional 124,809 shares during the last quarter. TD Asset Management Inc boosted its holdings in shares of Bicycle Therapeutics by 76.7% in the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock valued at $1,967,000 after purchasing an additional 42,200 shares during the last quarter. Perceptive Advisors LLC acquired a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at $11,577,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Bicycle Therapeutics by 275.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 97,392 shares of the company’s stock valued at $1,971,000 after acquiring an additional 71,434 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Bicycle Therapeutics by 97.2% during the 2nd quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock valued at $6,614,000 after acquiring an additional 161,100 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.